Overview
Cartalax is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, abbreviated AEDG) developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "cartilage tissue bioregulator" — part of a family of very short peptides designed by Khavinson's group to mimic naturally occurring tissue-specific regulatory peptides, on the theory that connective and cartilage tissue produces its own short peptide signals that decline with age and contribute to degenerative joint changes.
It is important to state plainly what the evidence base for Cartalax actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology,
Neuroscience and Behavioral Physiology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Cartalax as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Cartalax is studied mainly in aged rodent and in vitro chondrocyte models for effects on cartilage matrix markers, chondrocyte proliferation and viability, and musculoskeletal ageing more broadly, including some osteoarthritis-adjacent research contexts published within Russian gerontology sources. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human RCT (Russian, small-scale) |
✔ (limited) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Cartalax's proposed mechanism is not receptor-based in the way conventional pharmaceuticals are described. Khavinson's peptide bioregulator theory proposes that very short peptides (2-4 amino acids) can interact directly with gene promoter regions or chromatin, modulating transcription of genes relevant to the tissue the peptide is derived from — in this case, cartilage and connective tissue. This is a substantially different and far less mechanistically established framework than classical receptor pharmacology.
Preclinical papers from the Khavinson group report that Cartalax has been observed to support chondrocyte proliferation and extracellular matrix protein synthesis (including collagen type II and proteoglycan markers) in aged animal cartilage tissue and in vitro chondrocyte culture models. Proposed downstream effects include modulation of gene expression linked to cartilage matrix turnover and a reported reduction in markers of age-related cartilage degeneration in animal models. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Chondrocyte Function and Cartilage Matrix Markers
The bulk of Cartalax-specific research relates to chondrocyte proliferation and viability, and markers of cartilage extracellular matrix synthesis, in in vitro cell culture and aged rodent cartilage tissue. Reported findings describe has been observed to support in chondrocyte activity markers and matrix protein synthesis following Cartalax exposure, proposed to relate to gene-regulatory effects on cartilage-specific tissue.
Musculoskeletal Ageing Models
Several Khavinson-affiliated papers report reduced markers of age-related cartilage degeneration in aged rodent joint tissue given Cartalax, presented as evidence for a general connective-tissue-supportive research profile in ageing models.
Osteoarthritis-Adjacent Research Contexts
Cartalax has been referenced within Russian gerontology literature discussing joint tissue ageing and osteoarthritis-adjacent degenerative processes, though this remains a narrow and preliminary body of research rather than dedicated osteoarthritis clinical trial data. Reported outcomes in this context describe has been observed to support in cartilage tissue markers relative to untreated aged controls.
Research Data Summary
| Study / Model |
Reported Effect |
| Aged Rat Cartilage Tissue Model (Khavinson et al.) |
Reported increase in chondrocyte matrix protein synthesis markers relative to untreated aged controls. |
| In Vitro Chondrocyte Culture |
Reported support for chondrocyte proliferation and viability under experimental conditions. |
| Aged Rodent Joint Degeneration Model |
Reported reduction in markers of age-related cartilage matrix breakdown. |
| Gene Expression Analysis (Cartilage Tissue) |
Reported modulation of gene expression markers linked to cartilage matrix turnover. |
Stack Combinations Studied
- Cartalax + Ovagen → Research rationale: Explored in Russian gerontology literature as a combined connective-tissue and general-restorative bioregulator pairing, studied together for broader musculoskeletal ageing research aims.
- Cartalax + Vesugen → Research rationale: Both appear in the wider Khavinson bioregulator catalogue as tissue-specific pairings studied in some Russian protocols examining combined vascular and connective tissue ageing markers.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Chondrocyte and cartilage matrix marker studies in aged rodents. |
| Russian Small-Scale Human Study Protocol |
Reported in limited Russian clinical research settings; exact dosing not consistently published |
10-20 day course |
As per study protocol |
Reported in small Russian clinical research on musculoskeletal ageing markers; not independently replicated. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Long-term human safety data does not exist outside limited Russian research settings
Because independent Western toxicology and safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile.
Compound Data
- CAS Number
- Not consistently assigned in Western chemical registries
- Molecular Formula
- C13H21N3O9 (approximate; Ala-Glu-Asp-Gly tetrapeptide)
- Molecular Weight
- Approximately 391.3 g/mol
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Ala-Glu-Asp-Gly, AEDG peptide, cartilage tissue bioregulator peptide
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (cartilage/connective tissue) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al.] — Peptide regulation of cartilage tissue gene expression and chondrocyte function in ageing models — Bulletin of Experimental Biology and Medicine — [Animal / in vitro, Russian research programme]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework, tissue-specific bioregulator catalogue including Cartalax]
- [Khavinson VK et al.] — Short peptide bioregulators and markers of connective tissue ageing — Advances in Gerontology — [Animal / Russian research programme]
- [Umnov RS et al.] — Effects of tetrapeptide bioregulators on chondrocyte proliferation and matrix protein synthesis in vitro — Neuroscience and Behavioral Physiology — [In vitro]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*